Replies to post #15283 on Innovus Pharmaceuticals Inc. (fka INNV)

[awaitingamove]

I just refer you to this as well as the big developments in 2018 alone that we should begin to harvest as well as this new addition

First quarter 2018 and recent developments:

Received net cash proceeds of $2.8 million from the exercise of warrants to purchase shares of the Company’s common stock, raised net cash proceeds of $1.9 million from the issuance of notes payable during the first quarter of 2018 and current total cash on hand is $4.9 million;
Entered into an exclusive license and distribution agreement with Acerus Pharmaceuticals in January 2018 granting them exclusive rights to market and sell UriVarx® in Canada;
Entered into an exclusive license and distribution agreement with Lavasta Pharma in January 2018 granting them exclusive rights to market and sell ProstaGorx® in various countries in the Middle East and North Africa;
Launched seven new products;
Received multiple product approvals in Canada; and
Expanded our Beyond Human™ sales and marketing platform to Canada and launched three products there.